medigraphic.com

2019, Number 4

<< Back Next >>

Rev Fac Med UNAM 2019; 62 (4)

The prostate: generalities and most frequent pathologies

Robles RA, Garibay HTR, Acosta AE, Morales LS

Language: Spanish
References: 27
Page: 41-54
PDF size: 376.40 Kb.


ABSTRACT

The prostate is a fibromuscular and glandular organ that produces a liquid secretion that is part of the semen, it contains substances that provide nutrients and an adequate medium for the survival of the sperm. This pathology is one of the most frequent reasons for consultation in family medicine and urology, so it is important to recognize the main clinical data to be able to make differential diagnoses between prostatic hyperplasia, prostate cancer and prostatitis.
Prostatic hyperplasia (HP) is the non-malignant proliferation of epithelial cells and the stroma of the prostate gland related to the aging process of men.
The prevalence of HP increases with age; 50% of men aged between 51 and 60 have it. The mechanism by which HP can produce a bladder obstruction comprises two components: a static and a dynamic one. There are obstructive and irritative symptoms of the lower urinary tract that affect the quality of life of the patient, interfering with their daily activities and sleep patterns.
The anamnesis allows the clinicians to determine and evaluate the magnitude of these symptoms, constituting a fundamental stage of the diagnosis, hence the usefulness of using the IPSS (International Prostate Symptom Score).
and consistency. α-Adrenergic blockers and 5α-reductase inhibitors are the two types of drugs used.
Prostate cancer (PC) is the most frequent malignant tumor in men of 50 years old and its maximum peak is after 65 years. Its incidence has increased in recent years due, in part, to the improvement in diagnostic techniques, the increase in life expectancy and other factors not so well known as environmental exposure, diet, lifestyle and genetics. The American Cancer Society recommends an APE with or without a digital rectal exam starting at the age 50. The American Urology Association recommends it starting at the age of 40 and a biopsy in patients with PSA equal to or greater than 4 ng / ml is also suggested.
The selection of the treatment depends on the tumor staging and category of the risk, the age of the patient, life expectancy, presence or absence of symptoms and the effects of the treatment options on the quality of life.
Acute bacterial prostatitis is associated with lower urinary tract infection. The classification of patients with prostatitis depends on the bacteriological study of the lower urinary tract; prostatitis syndromes can be classified into four main groups: acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS), asymptomatic inflammatory prostatitis and granulomatous prostatitis.
It represents the most frequent urological diagnosis in young males. The prevalence is 2-16% and represents 8% of urological consultations.


REFERENCES

  1. McAnnch J, Lue T. Smith y Tanagho. Urología general. 18 ed. México: Editorial Mc Graw Hill; 2013.

  2. Secretaría de Salud. GPC: Diagnóstico y tratamiento de la hiperplasia prostática benigna. México, 2009. Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/ CatalogoMaestro/176_GPC_HIPERPLASIA_PROSTATICA/ Gpc_hipertrofia_prostatica.pdf

  3. Roehrborn CG, McConnell JD. Etiology, physiopathology, epidemiology and natural history of BPH. En: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. St Louis: WB Saunders 2007.

  4. Djavan B, et al., Benign prostatic hyperplasia: current clinical practice. - Prim Care SEP, 2010; 37(3):583-97.

  5. Masumori, Naoya et al. Natural history of benign prostatic hyperplasia - Journal of Men’s Health - April, 2011; 8(Suppl 1); S19-S21.

  6. Anderson, J. B., Roehrborn, C. G., Schalken, J. A., Emberton, M. The progression of benign prostatic hyperplasia. European Urology. 2011; 39:390-9.

  7. Keen CL., Diet and benign prostatic hyperplasia. Urology, 2011; 54:284-90.

  8. Valle Blasco M, et al. Abordaje de la hiperplasia benigna de próstata. Actuación Atención Primaria-Especializada Vol. 13 Núm. 3 Marzo 2003 MEDIFAM 2003; 13:133-142.

  9. Wei JT, Miner MM, Steers WD, et al. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol 2011; 186(3):971-976.

  10. Seisen T, Drouin SJ, Rouprêt M. EMC: Hipertrofia benigna de próstata - Tratado de Medicina Vol. 21, No.2, junio 2017. Descargado para Anonymous User (n/a) en Universidad Nacional Autónoma de México de ClinicalKey.es por Elsevier octubre 17, 2017.

  11. Secretaría de Salud. GPC: Prevención y detección temprana del cáncer de próstata en el primer nivel de atención. México 2013. Disponible en: http://www.cenetec.salud. gob.mx/descargas/gpc/CatalogoMaestro/140_GPC_CA_ PROSTATA/Gpc_ca_prostata.pdf

  12. Secretaría de Salud. GPC: Diagnóstico y Tratamiento del Cáncer de Próstata en un Segundo y tercer Nivel de Atención. México 2010. Disponible en: http://www.cenetec. salud.gob.mx/descargas/gpc/CatalogoMaestro/021_GPC_ CaProstata/SSA_021_08_EyR.pdf

  13. Gerhardt Attard MD, et al. Prostate cancer. Lancet 2016; 387:70-82.

  14. American Joint Committee on Cancer (AJCC): Prostate. In: Cancer Staging Manual. 7th ed. Chicago: Springer 2010.

  15. Morales-López S, et. al. Tacto rectal. Centro de Enseñanza y Certificación de Aptitudes Médicas, Departamento de Integración de Ciencias Médicas. UNAM. Disponible en: http://paginas.facmed.unam.mx/deptos/icm/images/ cecam/02.p.gine-andro/TACTO-RECTAL.pdf

  16. Seidel HM, et. al. Manual Mosby de Exploración física. Séptima edición. Editorial Elsevier.

  17. Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A, et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 2004; 111(2):310-5.

  18. Vallejos J, Villaronga A, Álvarez, Mariluis C, Paganini L, González C, De Luca S, Dieguez A. Staging of prostate cancer: An update. Rev Argent Radiol. 2013; 77:251-312.

  19. Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL. Urology 2005; 66(4):803-7. PubMed.

  20. Zonana-Nacach A, Figueroa-Torres CA, Méndez-Martini NP, López-Manjarrez J. Prostate biopsy and relation to prostate-specific antigen in patients diagnosed with benign prostatic hyperplasia. Revista Mexicana de Urología 2014; 74 (3):141-145.

  21. Rouprêt M, Phé V. Prostatitis y epididimitis. Tratado de Medicina Descargado para Universidad Nacional Autónoma de México, de: ClinicalKey.es por Elsevier noviembre 2017.

  22. Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents 2008; 31(suppl1):S85-S90.

  23. Skerk V, Schönwald S, Krhen I, Markovinovic´ L, Beus A, Kuzmanovic´ NS, et al. A etiology of chronic prostatitis. Int J Antimicrob Agents 2002; 19:471-4.

  24. Diagnóstico y Tratamiento de la prostatitis aguda. México Secretaría de Salud; 12 diciembre 2013. Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/ CatalogoMaestro/SS-683-PROSTATITIS_AGUDA/ GER_SS_683_13_Diagnostico_y_tratamiento_de_la_ prostatitis_aguda.pdf

  25. Schaeffer AJ, Weidner W, Barbalias GA, Botto H, Johansen TE, Hochreiter WW, et al. Summary consensus statement: diagnosis and management of chronic prostatitis/ chronic pelvic pain syndrome. Eur Urol 2003; 2:1-4.

  26. Brede CM, Shoskes DA. The etiology and management of acute prostatitis. Nat Rev Urol 2011; 8:207-12.

  27. Grabe M, Bjerklund-Johansen TE, Botto H, Cek M, Naber KG, Pickard RS, et al. Guidelines on Urological Infections. Eur Assoc Urol, 2013.




2020     |     www.medigraphic.com